Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma

International Journal of Cancer

Volumn 137, Issue 11, 2015, Pages 2607-2617

  Wagner, Nikolaus B ^a,b   Weide, Benjamin ^c   Reith, Maike ^a,b   Tarnanidis, Kathrin ^a,b   Kehrel, Coretta ^a,b   Lichtenberger, Ramtin ^a,b   Pflugfelder, Annette ^c   Herpel, Esther ^d,e   Eubel, Jana ^e   Ikenberg, Kristian ^f   Busch, Christian ^c   Holland Letz, Tim ^a   Naeher, Helmut ^e   Garbe, Claus ^c   Umansky, Viktor ^a   Enk, Alexander ^e   Utikal, Jochen ^a,b   Gebhardt, Christoffer ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Tissue Bank National Centre for Tumour Diseases (NCT)   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

biomarker; melanoma; overall survival; RAGE; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE; CYSTEINE; TYROSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEVUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; ADOLESCENT; AGED; DISEASE COURSE; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; UP-REGULATION; YOUNG ADULT;

EID: 84941670947     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29619     Document Type: Article

References (52)

1. Villanueva J, Herlyn M., Melanoma and the tumor microenvironment. Curr Oncol Rep 2008; 10: 439-46.
2. Eggermont AM, Spatz A, Robert C., Cutaneous melanoma. Lancet 2014; 383: 816-27.
3. Ugurel S, Utikal J, Becker JC., Tumor biomarkers in melanoma. Cancer Control 2009; 16: 219-24.
4. Weide B, Elsasser M, Buttner P, et al., Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 2012; 107: 422-8.
5. Gebhardt C, Lichtenberger R, Utikal J., Biomarker Value and Pitfalls of Serum S100B in the Follow-Up of High-risk Melanoma Patients. JDDG, in press.
6. Gebhardt C, Riehl A, Durchdewald M, et al., RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-85.
7. Bierhaus A, Humpert PM, Morcos M, et al., Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-86.
8. Kierdorf K, Fritz G., RAGE regulation and signaling in inflammation and beyond. J Leukocyte Biol 2013; 94: 55-68.
9. Raucci A, Cugusi S, Antonelli A, et al., A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-27.
10. Hudson BI, Carter AM, Harja E, et al., Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22: 1572-80.
11. Humpert PM, Djuric Z, Kopf S, et al., Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6: 9
12. Bianchi ME., DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukocyte Biol 2007; 81: 1-5.
13. Sims GP, Rowe DC, Rietdijk ST, et al., HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
14. Gebhardt C, Nemeth J, Angel P, et al., S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72: 1622-31.
15. Hofmann MA, Drury S, Fu C, et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
16. Hudson BI, Stickland MH, Grant PJ, et al., Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes. Diabetes 2001; 50: 2646-51.
17. Hofmann MA, Drury S, Hudson BI, et al., RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immunity 2002; 3: 123-35.
18. Pettersson-Fernholm K, Forsblom C, Hudson BI, et al., The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003; 52: 891-4.
19. Dabritz J, Friedrichs F, Weinhage T, et al., The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn's disease. Am J Physiol 2011; 300: G823-32.
20. Park SJ, Kleffmann T, Hessian PA., The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant. J Biol Chem 2011; 286: 21384-92.
21. Li K, Dai D, Zhao B, et al., Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transmission 2010; 117: 97-104.
22. Kankova K, Vasku A, Hajek D, et al., Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 1999; 22: 1745.
23. Balch CM, Gershenwald JE, Soong SJ, et al., Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
24. Bubendorf L, Nocito A, Moch H, et al., Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001; 195: 72-9.
25. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, et al., Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer 2010; 10: 341.
26. Tesarova P, Kalousova M, Jachymova M, et al., Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 2007; 25: 720-5.
27. Hothorn T, Lausen B., On the exact distribution of maximally selected rank statistics. Computat Stat Data Anal 2003; 43: 121-37.
28. Robin X, Turck N, Hainard A, et al., pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform 2011; 12: 77
29. Pullerits R, Bokarewa M, Dahlberg L, et al., Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7: r817-24.
30. Coussens LM, Zitvogel L, Palucka AK., Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (New York, N.Y.) 2013; 339: 286-91.
31. Bald T, Quast T, Landsberg J, et al., Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014; 507: 109-13.
32. Kuniyasu H, Oue N, Wakikawa A, et al., Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 163-70.
33. Hsieh HL, Schafer BW, Sasaki N, et al., Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003; 307: 375-81.
34. Arumugam T, Simeone DM, Schmidt AM, et al., S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004; 279: 5059-65.
35. Bhawal UK, Ozaki Y, Nishimura M, et al., Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology 2005; 69: 246-55.
36. Tateno T, Ueno S, Hiwatashi K, et al., Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16: 440-6.
37. Abe R, Shimizu T, Sugawara H, et al., Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004; 122: 461-7.
38. Leclerc E, Heizmann CW, Vetter SW., RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen Physiol Biophys 2009; 28: f65-75. Spec No Focus:
39. Turovskaya O, Foell D, Sinha P, et al., RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-43.
40. DiNorcia J, Lee MK, Moroziewicz DN, et al., RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg 2012; 16: 104-12. discussion 12.
41. Kang R, Loux T, Tang D, et al., The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci USA 2012; 109: 7031-6.
42. Jing R, Cui M, Wang J, Wang H., Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 2010; 57: 55-61.
43. Krechler T, Jachymova M, Mestek O, et al., Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 2010; 43: 882-6.
44. Grote VA, Nieters A, Kaaks R, et al., The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort. Cancer Epidemiol, Biomarkers Prev 2012; 21: 619-28.
45. Donato R, Cannon BR, Sorci G, et al., Functions of S100 proteins. Curr Mol Med 2013; 13: 24-57.
46. Taguchi A, Blood DC, del Toro G, et al., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
47. Yamamoto Y, Doi T, Kato I, et al., Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann N Y Acad Sci 2005; 1043: 5626.
48. Gast A, Scherer D, Chen B, et al., Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 2010; 49: 733-45.
49. Gu H, Yang L, Sun Q, et al., Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res 2008; 14: 3627-32.
50. Wang X, Cui E, Zeng H, et al., RAGE Genetic Polymorphisms Are Associated with Risk, Chemotherapy Response and Prognosis in Patients with Advanced NSCLC. PloS One 2012; 7: e43734.
51. Saha A, Lee YC, Zhang Z, et al., Lack of an endogenous anti-inflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs. J Biol Chem 2010; 285: 10822-31.
52. Bjork P, Kallberg E, Wellmar U, et al., Common interactions between S100A4 and S100A9 defined by a novel chemical probe. PloS One 2013; 8: e63012.